25 Jan 2010 07:00
ο»Ώ
25 January 2010Β
Scientific Digital Imaging plc
("SDI" or the "Group")
(AIM: SDI)
UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS TOΒ 31 OCTOBER 2009
The Board of Scientific Digital Imaging plc, theΒ AIMΒ quoted group focused on the needs of the scientific community, is pleased to announce its unaudited interim results for the six months endedΒ 31 October 2009.
Highlights
Sales increased by 7.0% to Β£3.42m (2008: Β£3.19m)
Gross margins improved to 57.8% (2008: 54.3%)
Synergies from earlier acquisitions became more evident
Operating profit Β£75k (2008: Β£270k, which benefited from a currency exchange gain of Β£110k)
Basic earnings per share 0.69p (2008: 1.37p)
Net cash position Β£163kΒ
Harry TeeΒ CBE, Chairman of SDI, commented:
"Overall, we believe that the Group has strengthened its market position over the past six months and that its new products and initiatives provide considerable potential for profitable growth.
"We continue to seek further complementary acquisition targets for the Group."
--END-
Enquiries
Scientific Digital Imaging plc Β
01223 727144
Harry TeeΒ CBE, Chairman
Phil Atkin,Β CEO
www.scientificdigitalimaging.comΒ
GrantΒ ThorntonΒ Corporate FinanceΒ (Nominated Adviser)
020 7383 5100
Philip Secrett
Colin Aaronson
Astaire Securities plc
020 7448 4400Β
Katie Shelton Β
Bishopsgate Communications
020 7562 3350
Will Tindall
Gemma O'Hara
sdi@bishopsgatecommunications.com
Β
Chairman's statement
Unaudited for the six months endedΒ 31 October 2009
I am pleased to report that the Group showed a sales increase of 7.0% to Β£3.42m (2008: Β£3.19m) in the six months toΒ 31 October 2009, despite the gloomy economic environment.Β Operating profit reduced to Β£75k (2008: Β£270k); the reduction was a consequence of currency exchange movements between the periodsΒ of Β£142k and increased investment in the Group's future. Basic earnings per share were 0.69p and fully diluted 0.60p (2008: 1.37p in both cases). The Group's net cash position decreased by Β£176k to Β£163k over the period. This reduction included a final consideration payment of Β£23k for the completion of the acquisition of Atik (formerly known as Artemis and Perseu), whilst working capital absorbed Β£96k.
Trading
Synoptics Limited ("Synoptics"), the Group's primary subsidiary, saw a small increase in its contribution margin despite a slight decrease in sales, whereas Atik demonstrated good improvements in both margin and turnover and provided a solid contribution to Group results.
Gross margin percentages improved by 3.5% to 57.8% (2008: 54.3%) as a result of product mix changes and the inclusion of Atik - a key supplier of Synoptics - within the Group, together with more advantageous exchange rates.
Administrative expenses increased to Β£1.87m (2008: Β£1.53m). A significant proportion of this rise is attributable to the administrative expenses of Atik and the ongoing listing costs ofΒ AIM; these were incurred over the full reporting period whereas the comparable 2008 figure only includes these expenses over the last part of that period. The Group also accelerated investment at Atik, increasing the number of employees from 3 to 7 since acquisition, in order to strengthen its sales channels and development capability. Costs denominated in US dollars also rose by approximately Β£60k as the result of changes in the exchange rate.Β
TheΒ SynopticsΒ businessΒ in the US continued to grow. In the Syngene division, sales of higher-value systems have increased; this is a result of an investment in key developments in this area that deliver both greater performance and improved ease of use. The availability of stimulus funds has also provided some boost to sales in theΒ US.
Atik has recently invested in a campaign to grow sales in the importantΒ USΒ market, using the facilities of Synoptics Inc. inΒ MarylandΒ to streamline operations. It has begun work on its own image processing package, "Dawn", that will further establish Atik as a key company in the amateur astronomy market. "Dawn" uses the facilities of the image processing software toolkit developed over many years by Synoptics (a key part of its intellectual property) to provide facilities for the post-processing of astronomical images, presented via an attractive and innovative user interface.
The Synbiosis (microbiology) division of Synoptics launched a major new product, ProtoCOL 2, following a considerable investment in optical, mechanical and especially software technology. ProtoCOL 2 is a complete redesign of the previous successful colony counting instrument. Not only does the instrument provide high performance levels, but every effort has been dedicated to making it easy to use for both the end customer and the distributors that sell it. Market feedback has so far been very encouraging and sales are satisfactory.
Outlook
The benefits we anticipated from the consolidation of key suppliers into the Group have begun to be realised. Not only has this improved margins, but technical synergies have been achieved. The development of ProtoCOL 2 is expected to strengthen our standing in the microbiology market place. We anticipate that this innovative newΒ product, along with improvements to the high-value products in the Syngene range and both new products and new sales channels at Atik, will result in further growth.
We are pleased that our sales have proved robust through turbulent economic periods. Our experiences suggest that the funding of long-term research and development in our key markets has so far remained insulated from the general fluctuations of the economy.Β
Overall, the Board believes the Group has strengthened its market position over recent periods and its new products and initiatives will contribute to a stronger second half. The Board now anticipates that market expectations for the full year will be exceeded. The Group continues to work on implementing its strategy to grow through acquisition and is actively seeking complementary businesses.Β
consolidated Income statement
Unaudited for the six months endedΒ 31 October 2009
|
Unaudited |
|
|
|
6 months toΒ 31 October 2009 |
6 months toΒ 31 October 2008 |
12 months toΒ 30 April 2009 |
|
|
|
|
|
Β£ |
Β£ |
Β£ |
|
Continuing operations |
|
|
|
|
|
|
|
Revenue |
|
|
|
3,417,800 |
3,192,820 |
6,753,869 |
|
Costs of sales |
|
|
|
(1,440,890) |
(1,458,007) |
(2,946,222) |
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
|
1,976,910 |
1,734,813 |
3,807,647 |
|
|
|
|
|
|
|
|
|
AIM listing expenses |
|
|
|
- |
(41,958) |
(344,956) |
|
Currency exchange gains and losses |
|
|
|
(31,746) |
110,533 |
183,077 |
|
Administrative expenses |
|
|
|
(1,869,828) |
(1,533,562) |
(3,539,519) |
|
Operating profit |
|
|
|
75,336 |
269,826 |
106,249 |
|
|
|
|
|
|
|
|
|
Financial income |
|
|
|
70 |
5,458 |
4,677 |
|
Financial expensesΒ |
|
|
|
(32,208) |
(20,064) |
(54,137) |
|
|
|
|
|
|
|
|
|
Profit before taxation |
|
|
|
43,198 |
255,220 |
56,789 |
|
|
|
|
|
|
|
|
|
Income tax expense |
1 |
|
|
68,260 |
(30,655) |
(49,077) |
|
|
|
|
|
|
|
|
|
Profit for the period |
|
|
|
111,458 |
224,565 |
7,712 |
|
|
|
|
|
|
|
|
|
Earnings per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BasicΒ Β |
2 |
|
|
0.69p |
1.37p |
0.05p |
|
DilutedΒ |
|
|
|
0.60p |
1.37P |
0.04p |
|
|
|
|
|
|
|
|
consolidated statement of comprehensive income
Unaudited for the six months endedΒ 31 October 2009
|
Unaudited |
|
|
|
6 months toΒ 31 October 2009 |
6 months toΒ 31 October 2008 |
12 months toΒ 30 April 2009 |
|
|
|
|
|
Β£ |
Β£ |
Β£ |
|
|
|
|
|
|
|
|
|
Profit for the period |
|
|
|
111,458 |
224,565 |
7,712 |
|
|
|
|
|
|
|
|
|
Other comprehensive income |
|
|
|
|
|
|
|
Exchange differences on translating foreign operations |
|
|
|
(46,683) |
(2,993) |
17,993 |
|
|
|
|
|
|
|
|
|
Total comprehensive income for the period |
|
|
|
64,775 |
221,572 |
25,705 |
|
|
|
|
|
|
|
|
consolidated balance sheetΒ
Unaudited atΒ 31 October 2009
|
Unaudited |
Note |
|
31 OctoberΒ 2009Β |
31 OctoberΒ 2008 |
30 AprilΒ 2009 |
|
Assets |
|
|
|
|
|
|
Non-current assets |
|
|
Β£ |
Β£ |
Β£ |
|
Property, plant and equipment |
|
|
348,464 |
285,789 |
334,379 |
|
Intangible assets |
|
|
740,308 |
666,982 |
702,058 |
|
Deferred tax asset |
|
|
117,102 |
22,959 |
22,959 |
|
|
|
|
1,205,874 |
975,730 |
1,059,396 |
|
Current assets |
|
|
|
|
|
|
Inventories |
|
|
534,811 |
528,317 |
508,710 |
|
Trade and other receivables |
|
|
1,254,086 |
1,376,880 |
1,244,846 |
|
Cash and cash equivalents |
|
|
602,396 |
872,569 |
756,686 |
|
|
|
|
2,391,293 |
2,777,766 |
2,510,242 |
|
|
|
|
|
|
|
|
Total assets |
|
|
3,597,167 |
3,753,496 |
3,569,638 |
|
|
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
Current liabilitiesΒ |
|
|
Β |
Β |
Β |
|
Trade and other payables |
|
|
1,081,121 |
1,184,493 |
1,171,110 |
|
Provisions forΒ warranty |
|
|
12,500 |
12,500 |
12,500 |
|
Borrowings |
3 |
|
26,855 |
30,945 |
30,148 |
|
Tax liabilities |
|
|
18,716 |
1,546 |
11,188 |
|
|
|
|
1,139,192 |
1,229,484 |
1,224,946 |
|
Non-current liabilitiesΒ |
|
|
|
|
|
|
BorrowingsΒ |
3 |
|
412,729 |
393,571 |
387,169 |
|
Deferred tax liability |
|
|
121,898 |
98,225 |
111,101 |
|
|
|
|
534,627 |
491,796 |
498,270 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
1,673,819 |
1,721,280 |
1,723,216 |
|
|
|
|
|
|
|
|
Net assets |
|
|
1,923,348 |
2,032,216 |
1,846,422 |
|
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
|
Share capital |
|
|
180,158 |
166,638 |
166,638 |
|
Merger reserve |
|
|
2,606,016 |
2,606,016 |
2,606,016 |
|
Share premium account |
|
|
187,142 |
38,327 |
38,327 |
|
Foreign exchange reserve |
|
|
(31,638) |
(5,941) |
15,045 |
|
Own shares held by Employee Benefit Trust |
|
|
(85,383) |
(85,383) |
(85,383) |
|
Other reserves |
|
|
248,940 |
389,051 |
399,124 |
|
Retained earningsΒ |
|
|
(1,181,887) |
(1,076,492) |
(1,293,345) |
|
|
|
|
|
|
|
|
Total Equity |
|
|
1,923,348 |
2,032,216 |
1,846,422 |
|
|
|
|
|
|
|
consolidated statement of CASH FLOWs
Unaudited for the six months endedΒ 31 October 2009
|
Unaudited |
6Β monthsΒ toΒ 31 OctoberΒ 2009 |
6Β monthsΒ toΒ 31 OctoberΒ 2008 |
12 months toΒ 30 AprilΒ 2009 |
|
|
Β£ |
Β£ |
Β£ |
|
Operating activities |
|
|
|
|
Profit for the period |
111,458 |
224,565 |
7,712 |
|
Depreciation and amortisationΒ |
125,858 |
90,692 |
195,522 |
|
Profit on sale of property, plant and equipment |
(2,811) |
- |
(12,145) |
|
FinanceΒ expense |
32,138 |
14,606 |
49,460 |
|
Taxation expenseΒ recognisedΒ in the income statement |
(68,260) |
30,655 |
49,077 |
|
Increase in warranty provision |
- |
2,500 |
2,500 |
|
Foreign exchange loss |
(18,856) |
(8,595) |
(4,918) |
|
Employee share based paymentsΒ |
9,776 |
9,475 |
15,346 |
|
Operating cash flow before movement in working capital |
189,303 |
363,898 |
302,554 |
|
(Increase)Β /Β Decrease in inventoriesΒ |
(34,996) |
(40,480) |
5,137 |
|
Changes in trade and other receivables |
(33,652) |
(3,264) |
(68,205) |
|
Changes in trade and other payables |
(27,541) |
(42,589) |
157,506 |
|
Cash generated from operations |
93,114 |
277,565 |
396,992 |
|
|
|
|
|
|
Interest paid |
(28,247) |
(18,698) |
(48,704) |
|
Income taxesΒ paid |
(26,797) |
- |
(7,730) |
|
Cash generated from operating activities |
38,070 |
258,867 |
340,558 |
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Purchase of property plant and equipment |
(98,949) |
(83,296) |
(237,915) |
|
Investment in development |
(88,455) |
(81,746) |
(148,466) |
|
Proceeds from saleΒ of property, plant and equipment |
33,427 |
45,676 |
109,351 |
|
Purchase of acquisitions, net of cash acquired |
(23,313) |
(50,692) |
(74,025) |
|
Interest received |
70 |
5,458 |
4,600 |
|
Net cash used in investing activities |
(177,220) |
(164,600) |
(346,455) |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Capital element of finance leases |
(17,515) |
(15,066) |
(30,785) |
|
Issues of shares and warrants |
2,375 |
41,659 |
41,659 |
|
Issue of loan stock |
- |
379,000 |
379,000 |
|
Net cashΒ used inΒ financingΒ activities |
(15,140) |
405,593 |
389,874 |
|
|
|
|
|
|
Net changes in cash and cash equivalents |
(154,290) |
499,860 |
383,977 |
|
Cash and cash equivalents, beginning ofΒ period |
756,686 |
372,709 |
372,709 |
|
Cash and cash equivalents, end of periodΒ |
602,396 |
872,569 |
756,686 |
consolidated statement of changes in equity
Unaudited as atΒ 31 October 2009
Β
|
Β
|
Β Share Capital
|
Merger Reserve
|
Share premium
|
Own shares held by EBT
|
Other Reserves
|
Foreign exchange
|
Retained Earnings
|
Total
|
|
Β
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
|
Balance at 1 May 2009
|
166,638
|
2,606,016
|
38,327
|
(85,383)
|
399,124
|
15,045
|
(1,293,345)
|
1,846,422
|
|
Share issued as deferred payment
|
13,330
|
-
|
146,630
|
-
|
(159,960)
|
-
|
-
|
-
|
|
Share options exercised
|
190
|
-
|
2,185
|
-
|
-
|
-
|
-
|
2,375
|
|
Share based payments
|
-
|
-
|
-
|
-
|
9,776
|
-
|
-
|
9,776
|
|
Transactions with owners
|
13,520
|
-
|
148,815
|
-
|
(150,184)
|
-
|
-
|
12,151
|
|
Profit for the period
|
-
|
-
|
-
|
-
|
-
|
-
|
111,458
|
111,458
|
|
Foreign exchange on consolidation of subsidiary
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
(46,683)
|
-
Β
|
Β
(46,683)
|
|
Total comprehensive income for the period
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
(46,683)
|
Β
111,458
|
Β
64,775
|
|
Balance at 31 October 2009
|
Β
180,158
|
Β
2,606,016
|
Β
187,142
|
Β
(85,383)
|
Β
248,940
|
Β
(31,638)
|
Β
(1,181,887)
|
Β
1,923,348
|
|
Β
Β
|
Share Capital
|
Merger Reserve
|
Share premium
|
Own shares held by EBT
|
Other Reserves
|
Foreign exchange
|
Retained Earnings
|
Total
|
|
Β
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
|
Balance at 1 May 2008
|
163,306
|
2,606,016
|
-
|
(250,147)
|
22,872
|
(2,948)
|
(1,136,293)
|
1,402,806
|
|
Deferred tax on options
|
-
|
-
|
-
|
-
|
(4,202)
|
-
|
-
|
(4,202)
|
|
Employee Benefit Trust adjustment
|
-
|
-
|
-
|
Β
164,764
|
-
|
-
|
Β
(164,764)
|
-
|
|
Deferred consideration on acquisitions
|
-
|
-
|
-
|
-
|
Β
319,920
|
-
|
-
|
Β
319,920
|
|
Share options exercised
|
3,332
|
-
|
38,327
|
-
|
-
|
-
|
-
|
41,659
|
|
Share based payments
|
-
|
-
|
-
|
-
|
9,475
|
-
|
-
|
9,475
|
|
Equity element of loan stock
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
40,986
|
Β
-
|
Β
-
|
Β
40,986
|
|
Transactions with owners
|
3,332
|
Β
|
38,327
|
164,764
|
366,179
|
-
|
(164,764)
|
407,838
|
|
Profit for the period
|
-
|
-
|
-
|
-
|
-
|
-
|
224,565
|
224,565
|
|
Foreign exchange on consolidation of subsidiary
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
(2,993)
|
Β
-
|
Β
(2,993)
|
|
Total comprehensive income for the period
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
(2,993)
|
Β
224,565
|
Β
221,572
|
|
Balance at 31 October 2008
|
166,638
|
2,606,016
|
38,327
|
(85,383)
|
389,051
|
(5,941)
|
(1,076,492)
|
2,032,216
|
|
Β
|
Share Capital
|
Merger Reserve
|
Share premium
|
Own shares held by EBT
|
Other Reserves
|
Foreign exchange
|
Retained Earnings
|
Total
|
|
Β
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
Β£
|
|
Balance at 1 May 2008
|
163,306
|
2,606,016
|
-
|
(250,147)
|
22,872
|
(2,948)
|
(1,136,293)
|
1,402,806
|
|
Deferred tax on options
|
-
|
-
|
-
|
-
|
(4,203)
|
-
|
-
|
(4,203)
|
|
Employee Benefit Trust adjustment
|
-
|
-
|
-
|
Β
164,764
|
-
|
-
|
Β
(164,764)
|
-
|
|
Deferred consideration on acquisitions
|
-
|
-
|
-
|
-
|
Β
319,920
|
-
|
-
|
Β
319,920
|
|
Equity element of loan stock
|
-
|
-
|
-
|
-
|
Β
40,986
|
-
|
-
|
Β
40,986
|
|
Share options exercised
|
3,332
|
-
|
38,327
|
-
|
-
|
-
|
-
|
41,659
|
|
Share based payments
|
-
|
-
|
-
|
-
|
19,549
|
-
|
-
|
19,549
|
|
Transactions with owners
|
3,332
|
-
|
38,327
|
164,764
|
376,252
|
-
|
(164,764)
|
417,911
|
|
Profit for the period
|
-
|
-
|
-
|
-
|
-
|
-
|
7,712
|
7,712
|
|
Foreign exchange on consolidation of subsidiary
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
-
|
Β
17,993
|
Β
-
|
Β
17,993
|
|
Total comprehensive income
|
-
|
-
|
-
|
-
|
-
|
17,993
|
7,712
|
25,705
|
|
Balance at 30 April 2009
|
166,638
|
2,606,016
|
38,327
|
(85,383)
|
399,124
|
15,045
|
(1,293,345)
|
1,846,422
|
Β
notes to the interim financial statementsΒ
Unaudited as atΒ 31 October 2009
The accompanying accounting policies and notes form an integral part of these interim financial statements.
reporting entity
Scientific Digital Imaging plc, a public limited company, is the Group's ultimate parent. It is registered inΒ EnglandΒ andΒ Wales. The consolidated interim financial statements of the Company for the period endedΒ 31 October 2009Β comprise the Company and its subsidiaries (together referred to as the "Group").Β
Basis of Preparation
The unaudited consolidated interim financial statements are for the six months endedΒ 31 October 2009. These interim financial statements have been prepared in accordance with the accounting policies expected to be followed for the year endingΒ 30 April 2010, which are based on the recognition and measurement principles of IFRS as adopted by the European Union. The financial information for the year endedΒ 30 April 2009Β is based upon the audited statutory accounts for that year.
The financial statements have been prepared on the historical cost basis.
The consolidated interim financial statements are presented in British pounds (Β£), which is also the functional currency of the ultimate parent company.
The consolidated interim financial information was approved by The Board of Directors onΒ 22ndΒ January 2010.
The financial information set out in this interim report does not constitute statutory accounts as defined in sectionΒ 434Β of the Companies ActΒ 2006. The figures for the year endedΒ 30 April 2009Β have been extracted from the IFRS Statutory Financial Statements of Scientific Digital Imaging Plc which have been filed with the Registrar of Companies. The auditor's report on those financial statements is unqualified. The financial information for the six months toΒ 31 October 2009Β and for the six months toΒ 31 October 2008Β is unaudited.
principal accounting policies
The principal accounting policies adopted are consistent with those of the annual financial statements for the year ended 30 April 2009,Β except for the adoption of IAS 1 Presentation of Financial Statements (revised 2007) and IFRS 8 Operating Segments, and are those expected to be applied for the year ended 30 April 2010.
The adoption of IAS 1 (revised 2007) does not affect the financial position orΒ the profits of the Group, but gives rise to additional disclosures. The measurement and recognition of the Group's assets, liabilities, income and expenses is unchanged. IAS 1 (revised 2007) affects the presentation of owner changes in equity.Β
The adoption of IFRS 8 has not changed the segments which are disclosed. Under IFRS 8 the accounting policy for identifying segments is based on the internal management reporting information that is regularly reviewed by the chief operating decision maker.
Β The accounting policies have been applied consistently throughout the Group for the purposes of preparation of these interim financial statements.
1 TaxATION
Β
|
Β
|
6 mths to October
2009
|
6 mths to October
2008
|
year to
30 April 2009
|
|
Β
|
Β£
|
Β£
|
Β£
|
|
Current tax expenses
|
15,086
|
680
|
6,660
|
|
Deferred tax (income) / expenses
|
(83,346)
|
29,975
|
42,417
|
|
Β
|
Β
|
Β
|
Β
|
|
Income tax (credit) / charge
|
(68,260)
|
30,655
|
49,077
|
The income tax expense recognised in the period is less thanΒ the effective rate ofΒ tax forΒ the group of 28% due to the availability of an additional deduction in the period for research and development and theΒ impact of initial recognitionΒ of tax losses brought forward across the group.
2 Earnings per share
The calculation of the basic earnings per share is based on the profits attributable to the shareholders of Scientific Digital ImagingΒ Plc divided by the weighted average number of shares in issue during the year, excluding shares held by the Synoptics Employee Benefit Trust. All earnings per share calculations relate to continuing operations of the Group.
|
|
|
|
Profits attributable to shareholders |
Weighted average number of shares |
BasicΒ earnings per share amount in pence |
|
Period endedΒ 31 October 2009 |
|
|
111,458 |
16,073,650 |
0.69 |
|
Period endedΒ 31 October 2008 |
|
|
224,565 |
16,441,655 |
1.37 |
|
Year endedΒ 30 April 2009 |
|
|
7,712 |
15,841,221 |
0.05 |
The calculation of diluted earnings per share is based on the profits attributable to the shareholders of Scientific Digital Imaging plc divided by the weighted average number of shares in issue during the year, as adjusted for dilutive share options, dilutive deferred consideration and shares held by the Synoptics Employee Benefit Trust.
|
|
|
|
|
|
Diluted earnings per share amount in pence |
|
PeriodΒ endedΒ 31 October 2009 |
|
|
|
|
0.60 |
|
Period endedΒ 31 October 2008 |
|
|
|
|
1.37 |
|
Year endedΒ 30 April 2009 |
|
|
|
|
0.04 |
The reconciliation of average number of ordinary shares used for basic and diluted earnings is as below:
|
|
31 October 2009 |
30 AprilΒ 2009 |
|
Weighted average number of ordinary shares used for basic earnings per share |
16,073,650 |
15,841,221 |
|
Weighted average number of shares held by Synoptics Employee Benefit Trust |
711,528 |
711,528 |
|
Weighted average number of ordinary shares used as deferred consideration |
1,333,000 |
1,333,333 |
|
Weighted average number of ordinary shares under option |
451,567 |
625,593 |
|
Weighted average number of ordinary shares used for diluted earnings per share |
18,569,745 |
18,511,675 |
As at theΒ 31Β October 2009Β & 2008Β the company hadΒ outstandingΒ exercisableΒ share options and warrants. UnderΒ IAS 33Β the dilutive earnings per shareΒ is calculatedΒ assumingΒ that allΒ such instrumentsΒ are exercised in full. In October 2008 the exerciseΒ price for the options and warrantsΒ wasΒ the same or above the average market share price for the companyΒ soΒ the share options and warrantsΒ wereΒ considered to be non dilutive.Β
TheΒ conversion of allΒ loan stockΒ would result in an increase in average weighted shares ofΒ 379,000. There would beΒ a corresponding increase in adjusted earnings due to the interest accruing thereon.Β The net effect is an enhancement of earningsΒ per share.
3 Borrowings
|
Β
|
31 October
2009
|
31 October 2008
|
30 April 2008
|
|
Β
|
Β£
|
Β£
|
Β£
|
|
Within one year
|
Β
|
Β
|
Β
|
|
Finance leases
|
26,855
|
30,945
|
30,148
|
|
Β
|
Β
|
Β
|
Β
|
|
After one year and within two years
|
Β
|
Β
|
Β
|
|
Loan stock
|
347,577
|
339,380
|
343,478
|
|
Other borrowings
|
65,152
|
54,191
|
43,691
|
|
Β
|
412,729
|
393,571
|
387,169
|
|
Β
|
Β
|
Β
|
Β
|
|
Total borrowings
|
439,584
|
424,516
|
417,317
|
Follow the stocks